We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
We expect Zoetis Inc. (ZTS - Free Report) to surpass expectations when it reports fourth-quarter 2021 results on Feb 15, before market opens.
Zoetis’ earnings surprise history has been excellent so far, having surpassed expectations in each of the trailing four quarters, with an average of 12.7%. In the last reported quarter, Zoetis delivered an earnings surprise of 13.6%.
In the trailing 12 months, shares of Zoetis have increased 25.3% against the industry’s 33.2% decline.
Image Source: Zacks Investment Research
Let's see how things have shaped up for this announcement.
Factors to Consider
Zoetis derives the majority of revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — United States and International.
Revenues in the last reported quarter increased year over year to $1.065 billion in the United States, a trend that most likely continued in the fourth quarter as well. The Zacks Consensus Estimate for revenues in the United States is pegged at $1.020 billion.
Zoetis’ international revenues in the last reported quarter increased year over year to $904 million. This trend is also expected to have continued in the to-be-reported quarter. The Zacks Consensus Estimate for international revenues stands at $884 million.
Strong sales of the dermatology portfolio — owing to increased sales of Apoquel and Cytopoint brands — strengthened the U.S. segment in the last reported quarter, a trend that most likely continued in the fourth quarter as well. Zoetis’ companion animal business has also been performing well, primarily owing to higher sales of Simparica Trio, a triple combination parasiticide for dogs.
In the last reported quarter, sales of livestock products declined year over year, a trend that most likely continued in the fourth quarter as well. Sales of poultry products also declined in the last reported quarter due to the expanded use of lower-cost alternatives for premium products, a trend that is expected to have continued in the to-be-reported quarter. Sales of cattle products also decreased year over year due to increased generic competition, a trend that most likely continued in the fourth quarter as well.
In the last reported quarter, sales of swine products declined year over year due to pricing pressure on anti-infectives and vaccines, a trend that is expected to have continued in the to-be-reported quarter.
For the International segment, sales of companion animal products increased in the last reported quarter. The trend is expected to have continued in the fourth quarter as well.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Zoetis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Zoetis has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate stand at 96 cents.
Zacks Rank: Zoetis currently carries a Zacks Rank #3.
Stocks to Consider
Here are a few stocks you may want to consider as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Cara Therapeutics’ loss per share estimates for 2022 have narrowed from $1.49 to $1.47 in the past 30 days. Cara Therapeutics topped earnings estimates in three of the last four quarters, delivering a surprise of 126.9%, on average.
Evelo Biosciences (EVLO - Free Report) has an Earnings ESP of +12.79% and a Zacks Rank #2.
Evelo Biosciences’ loss per share estimates for 2022 have narrowed from $2.19 to $2.12 in the past 30 days. Evelo Biosciences missed earnings estimates in each of the last four quarters, delivering a negative surprise of 13.2%, on average.
Vir Biotechnology (VIR - Free Report) has an Earnings ESP of +32.05% and a Zacks Rank #1.
In the past 30 days, earnings per share estimates of Vir Biotechnology for 2022 have increased from $4.77 to $6.53. In fact, Vir Biotechnology topped earnings estimates in two of the last four quarters and missed the mark on the other two occasions, delivering a surprise of 13%, on average.
Image: Shutterstock
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
We expect Zoetis Inc. (ZTS - Free Report) to surpass expectations when it reports fourth-quarter 2021 results on Feb 15, before market opens.
Zoetis’ earnings surprise history has been excellent so far, having surpassed expectations in each of the trailing four quarters, with an average of 12.7%. In the last reported quarter, Zoetis delivered an earnings surprise of 13.6%.
Zoetis Inc. Price and EPS Surprise
Zoetis Inc. price-eps-surprise | Zoetis Inc. Quote
In the trailing 12 months, shares of Zoetis have increased 25.3% against the industry’s 33.2% decline.
Let's see how things have shaped up for this announcement.
Factors to Consider
Zoetis derives the majority of revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — United States and International.
Revenues in the last reported quarter increased year over year to $1.065 billion in the United States, a trend that most likely continued in the fourth quarter as well. The Zacks Consensus Estimate for revenues in the United States is pegged at $1.020 billion.
Zoetis’ international revenues in the last reported quarter increased year over year to $904 million. This trend is also expected to have continued in the to-be-reported quarter. The Zacks Consensus Estimate for international revenues stands at $884 million.
Strong sales of the dermatology portfolio — owing to increased sales of Apoquel and Cytopoint brands — strengthened the U.S. segment in the last reported quarter, a trend that most likely continued in the fourth quarter as well. Zoetis’ companion animal business has also been performing well, primarily owing to higher sales of Simparica Trio, a triple combination parasiticide for dogs.
In the last reported quarter, sales of livestock products declined year over year, a trend that most likely continued in the fourth quarter as well. Sales of poultry products also declined in the last reported quarter due to the expanded use of lower-cost alternatives for premium products, a trend that is expected to have continued in the to-be-reported quarter. Sales of cattle products also decreased year over year due to increased generic competition, a trend that most likely continued in the fourth quarter as well.
In the last reported quarter, sales of swine products declined year over year due to pricing pressure on anti-infectives and vaccines, a trend that is expected to have continued in the to-be-reported quarter.
For the International segment, sales of companion animal products increased in the last reported quarter. The trend is expected to have continued in the fourth quarter as well.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Zoetis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Zoetis has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate stand at 96 cents.
Zacks Rank: Zoetis currently carries a Zacks Rank #3.
Stocks to Consider
Here are a few stocks you may want to consider as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Cara Therapeutics (CARA - Free Report) has an Earnings ESP of +5.24% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cara Therapeutics’ loss per share estimates for 2022 have narrowed from $1.49 to $1.47 in the past 30 days. Cara Therapeutics topped earnings estimates in three of the last four quarters, delivering a surprise of 126.9%, on average.
Evelo Biosciences (EVLO - Free Report) has an Earnings ESP of +12.79% and a Zacks Rank #2.
Evelo Biosciences’ loss per share estimates for 2022 have narrowed from $2.19 to $2.12 in the past 30 days. Evelo Biosciences missed earnings estimates in each of the last four quarters, delivering a negative surprise of 13.2%, on average.
Vir Biotechnology (VIR - Free Report) has an Earnings ESP of +32.05% and a Zacks Rank #1.
In the past 30 days, earnings per share estimates of Vir Biotechnology for 2022 have increased from $4.77 to $6.53. In fact, Vir Biotechnology topped earnings estimates in two of the last four quarters and missed the mark on the other two occasions, delivering a surprise of 13%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.